We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs, Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Daily Bulletin
    • Drug Industry Daily
  • Device News
    • Trending
    • Commercial Operations
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Daily Bulletin
    • FDAnews Device Daily Bulletin Premium
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Manchin Introduces Bill to Counter Controversial 2016 DEA Opioid Shipment Law

Manchin Introduces Bill to Counter Controversial 2016 DEA Opioid Shipment Law

March 6, 2018

Sen. Joe Manchin (D-W.V) introduced legislation on Monday that would  expand the Drug Enforcement Agency’s existing authority to act on suspicious shipments from “substantial likelihood” so the agency could act for “probable cause.”

The bill also would abolish provisions allowing a “corrective action plan,” which Manchin said slows the DEA’s response to problem shipments.

Manchin introduced the legislation in response to an earlier law sponsored by Rep. Tom Marino (R-Pa.) that critics said hindered the DEA’s enforcement abilities amid the opioid addiction crisis. Rep. Marino withdrew from consideration as White House drug czar due to controversy over his role in the law’s passage. Shortly after Marino’s withdrawal, Sen. Claire McCaskill (D-Mo.) introduced legislation that would have repealed the law outright.

In late February, the Justice Department wrote to House Energy and Commerce Committee Chairman Greg Walder (R-Ore.) suggesting alterations to the 2016 bill as part of a push to more aggressively address the opioid crisis. Manchin’s amendments align with the department’s recommendations.

View today's stories

Drugs Regulatory Affairs

Upcoming Events

  • 04Apr

    Optimizing Quality Control Operations with Unified Quality

  • 20Apr

    Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • NVIDIA and Medtronic to Develop Artificial Intelligence Solutions

  • FDA Approves Evkeeza for Kids With Ultra-Rare Cholesterol Disorder

  • GrayMatters Health’s Digital Therapy Device for PTSD Cleared

  • Dupixent Shows Positive Results in COPD Study

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing